| Identification | Back Directory | [Name]
β-Alanine, N-[4-[(1R)-1-[[4'-(1,1-dimethylethyl)-2,6-dimethyl[1,1'-biphenyl]-4-yl]oxy]-4,4,4-trifluorobutyl]benzoyl]- | [CAS]
872260-19-0 | [Synonyms]
β-Alanine, N-[4-[(1R)-1-[[4'-(1,1-dimethylethyl)-2,6-dimethyl[1,1'-biphenyl]-4-yl]oxy]-4,4,4-trifluorobutyl]benzoyl]- | [Molecular Formula]
C32H36F3NO4 | [MOL File]
872260-19-0.mol | [Molecular Weight]
555.63 |
| Hazard Information | Back Directory | [Uses]
(+)-Adomeglivant ((+)-LY2409021) is a potent and selective glycogenotropin receptor antagonist with glucose-lowering activity. (+)-Adomeglivant reduces fasting blood glucose levels in both healthy subjects and patients with type 2 diabetes. The use of (+)-Adomeglivant can help investigate the mechanisms of hyperglycemia in type 2 diabetes. The antagonistic effect of (+)-Adomeglivant makes it challenging to assess the metabolic consequences of postprandial hyperglycemia[1]. | [References]
[1] The glucagon receptor antagonist LY2409021 has no effect on postprandial glucose in type 2 diabetes DOI:10.1530/EJE-21-0865 |
|
|